PHARMACEUTICAL COMPOSITIONS OF METABOTROPIC GLUTAMATE 5 RECEPTOR (MGLU5) ANTAGONISTS OR A PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF ARE DISCLOSED. THE COMPOSITIONS CONTAIN THE THERAPEUTIC ACTIVE COMPOUND WITH NON-IONIC POLYMER AND IONIC POLYMER, BINDER AND FILLERS IN EITHER MATRIX PELLET, MATRIX TABLET OR COATED PELLETS. THE COMPOSITIONS PROVIDE A PH-INDEPENDENT IN VITRO RELEASE PROFILE WITH NMT 70 % IN ONE HOUR, NMT 85 % IN 4 HOUR, AND NLT 80 % IN 8 HOURS. THE COMPOSITIONS ARE USEFUL FOR THE TREATMENT OF CNS DISORDERS, SUCH AS TREATMENT-RESISTANT DEPRESSION (TRD) AND FRAGILE X SYNDROME.
